Catalent

Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and cell and gene therapies. Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. 

The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled-release formulations, as well as immediate-release tablets and capsules. 

The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

2007: The pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.

2012: Catalent acquired Aptuit, a clinical supply company.

2013: Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.

2014: The shares began trading on the NYSE on July 31st, under the ticker symbol CTLT. Catalent announced its initial public offering. In November, Catalent announced it had acquired Micron Technologies, a provider of particle-size engineering technologies.

2016: Catalent licensed the antibody-drug conjugate (ADC) to Triphase Accelerator to help with oncology development, and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.

2017: In September, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand its biologic manufacturing.

2018: In July, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.

2019: In March, Catalent invested more than $27 million to commercialize Zydis Ultra. In June, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO. Later that year, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method. Alessandro Maselli was appointed as president and chief operating officer, a newly created position within Catalent.

2020: In January, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies. In February, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson, AstraZeneca, and Moderna to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.

2021: In August, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. In October, Catalent opened a 6,000-square-meter clinical supply facility in Shiga, Japan.

To develop, manufacture and supply products that help people live better, healthier lives.

Our vision is to be the world’s most trusted, reliable and innovative drug development and delivery partner by upholding the highest industry standards and exceeding customer expectations while driving strong, sustained growth for the company.